Arecor Therapeutics (LSE:AREC) Change In Receivables : £-1.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Change In Receivables?

Arecor Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was £1.45 Mil. It means Arecor Therapeutics's Accounts Receivable declined by £1.45 Mil from Jun. 2023 to Dec. 2023 .

Arecor Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was £-1.00 Mil. It means Arecor Therapeutics's Accounts Receivable increased by £1.00 Mil from Dec. 2022 to Dec. 2023 .

Arecor Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was £2.27 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Arecor Therapeutics's Days Sales Outstanding for the six months ended in Dec. 2023 was 142.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Arecor Therapeutics's liquidation value for the six months ended in Dec. 2023 was £2.99 Mil.

Arecor Therapeutics Change In Receivables Historical Data

The historical data trend for Arecor Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Change In Receivables Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.31

0.38

-1.26

-0.05

-1.00

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial					-0.81	-0.04	-0.01	-2.46	1.45

Arecor Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.00 Mil.

Arecor Therapeutics (LSE:AREC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Arecor Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.268	/	2.904	*	91
=	142.53

2. In Ben Graham's calculation of liquidation value, Arecor Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Arecor Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.752	-	5.85	+	0.75 * 2.268	+	0.5 * 0.771
=	2.99

Arecor Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.